Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Ravoet

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Leukemia|July 1, 1995
Hematopoietic growth factors in drug-induced agranulocytosisA DeLannoy, C Ravoet
Journal of Surgical Oncology. Supplement|January 1, 1993
Non-surgical treatment of hepatocarcinomaC Ravoet, H Bleiberg, B Gerard
The New England Journal of Medicine|October 12, 1995
Heparin-induced thrombocytopeniaN Hougardy, J P Machiels, C Ravoet
European Journal of Haematology|February 1, 1995
Transjugular intrahepatic portosystemic stent-shunt in myeloid metaplasiaC Ravoet, J Devière, W Feremans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1995
CA-125 in primary mediastinal B-cell lymphoma with sclerosisC Ravoet, J L Dargent, F Le Moine, et al.
Blood|April 15, 1996
Predictive value of the steady-state peripheral blood progenitor cell (PBPC) counts for the yield of PBPC collected by leukapheresis after mobilization by granulocyte colony-stimulating factor (G-CSF) alone or chemotherapy and G-CSFB Husson, C Ravoet, M Dehon, et al.
Leukemia & Lymphoma|October 1, 2005
Translocation of BCL2 and BCL6 to the same immunoglobulin heavy chain locus in a case of follicular lymphomaK Rack, A Delannoy, C Ravoet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patientsP Wijermans, M Lübbert, G Verhoef, et al.
British Journal of Haematology|September 1, 2001
Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidineM Lübbert, P Wijermans, R Kunzmann, et al.
Acta Clinica Belgica|January 25, 2014
Management of myelodysplastic syndromes in adults: guidelines from the Belgian Haematological SocietyS Meers, D Breems, G Bries, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Leukemia|July 1, 1995
Hematopoietic growth factors in drug-induced agranulocytosisA DeLannoy, C Ravoet
Journal of Surgical Oncology. Supplement|January 1, 1993
Non-surgical treatment of hepatocarcinomaC Ravoet, H Bleiberg, B Gerard
The New England Journal of Medicine|October 12, 1995
Heparin-induced thrombocytopeniaN Hougardy, J P Machiels, C Ravoet
European Journal of Haematology|February 1, 1995
Transjugular intrahepatic portosystemic stent-shunt in myeloid metaplasiaC Ravoet, J Devière, W Feremans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1995
CA-125 in primary mediastinal B-cell lymphoma with sclerosisC Ravoet, J L Dargent, F Le Moine, et al.
Blood|April 15, 1996
Predictive value of the steady-state peripheral blood progenitor cell (PBPC) counts for the yield of PBPC collected by leukapheresis after mobilization by granulocyte colony-stimulating factor (G-CSF) alone or chemotherapy and G-CSFB Husson, C Ravoet, M Dehon, et al.
Leukemia & Lymphoma|October 1, 2005
Translocation of BCL2 and BCL6 to the same immunoglobulin heavy chain locus in a case of follicular lymphomaK Rack, A Delannoy, C Ravoet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patientsP Wijermans, M Lübbert, G Verhoef, et al.
British Journal of Haematology|September 1, 2001
Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidineM Lübbert, P Wijermans, R Kunzmann, et al.
Acta Clinica Belgica|January 25, 2014
Management of myelodysplastic syndromes in adults: guidelines from the Belgian Haematological SocietyS Meers, D Breems, G Bries, et al.
Pageof 3